Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced its participation in the following upcoming investor conferences:
- Needham & Company’s 17th Annual Healthcare Conference on Tuesday, March 27, 2018, at 1:30 p.m. Eastern Time, at the Westin Grand Central Hotel in New York, NY; and
- The H.C. Wainwright Global Life Sciences Conference on Monday, April 9, 2018, at 11:55 a.m. Central European Time, at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
A live webcast of the presentations will be available on the company’s website at www.akebia.com. To access the webcasts, please log onto the Akebia website at least 15 minutes prior to the webcast to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Akebia’s website following the conferences.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
John Garabo, 617-844-6130
Director, Corporate Communications